Migraine (ICD10) V1.3

To identify Parkinson's disease, a code list was created by José Ignacio Cuitún Coronado (Senior Research Associate in Medical Statistics and Applied Health Data Science, University of Bristol) and reviewed by Elizabeth Coulthard (Professor of Cognitive Neurology, University of Bristol).

Step 1. We searched for the following key term:

• Migraine
• Headache
• Moderate headache
• Severe headache

Step 2. We excluded irrelevant codes (e.g., codes indicating a prevalent diagnosis or where the diagnosis was unclear):

(A) Codes that identify a prevalent diagnosis:

• History of

(B) Codes that do not relate to the person:

• Family history

(C) Codes where the diagnosis is unclear:

• Assessment
• At risk
• Attendance
• Battery
• Tool
• Referral
• Invite / invitation

(D) Codes excluded upon review by the clinician:

• Society
• Committee
• Medication (partial exclusion)
• Substances (partial exclusion)
• Drugs (partial exclusion)
• Measure / measurement / test / scale questionnaire
• (Cluster headaches) or (migrainous neuralgia) or (migraine NOS)
• (Cluster headaches) or (migrainous neuralgia) or (migraine NOS)
• Agent for migraine
• Agent for migraine
• Agent for migraine
• Atypical cluster headache
• Chronic cluster headache
• Chronic cluster headache evolved from episodic cluster headache
• Chronic cluster headache unremitting from onset
• Clonidine HCl [migraine]
• Drug product - agent for migraine
• Drugs used in migraine prophylaxis
• Episodic cluster headache
• FH: Migraine
• Family history: Migraine
• Lower half migraine
• Medicinal product acting as antimigraine agent
• No history of migraine
• Product containing eptinezumab
• Product containing eptinezumab in parenteral dose form
• Product containing fremanezumab in parenteral dose form
• Product containing lasmiditan
• Product containing lasmiditan in oral dose form
• Product containing only eptinezumab
• Product containing only eptinezumab in parenteral dose form
• Product containing only fremanezumab in parenteral dose form
• Product containing only lasmiditan
• Product containing only lasmiditan in oral dose form
• Product containing only rimegepant
• Product containing only rimegepant in oral dose form
• Product containing only rimegepant in oromucosal dose form
• Product containing only ubrogepant
• Product containing only ubrogepant in oral dose form
• Product containing precisely lasmiditan 50 milligram/1 each conventional release oral tablet
• Product containing precisely rimegepant (as rimegepant sulfate) 75 milligram/1 each conventional release orodispersible tablet
• Product containing rimegepant
• Product containing rimegepant in oral dose form
• Product containing rimegepant in oromucosal dose form
• Product containing ubrogepant
• Product containing ubrogepant in oral dose form

No medication/drug/substance(s) were removed unless there was a clear example from the clinician.